Estrogen receptor alpha-36 (ER-α36): A new player in human breast cancer

Molecular and Cellular Endocrinology

Volumn 418, Issue , 2015, Pages 193-206

  Wang, Zhao Yi ^a   Yin, Li ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiestrogen resistance; Breast cancer stem progenitor cells; ER positive and negative breast cancer; ER 36; Rapid estrogen signaling

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA 46; ESTROGEN RECEPTOR ALPHA36; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR X; G PROTEIN COUPLED RECEPTOR 30; GROWTH FACTOR; TAMOXIFEN; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA 36, HUMAN;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER RESISTANCE; CANCER STEM CELL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN REGULATION; GENOME ANALYSIS; HUMAN; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; BREAST NEOPLASMS; CELL MEMBRANE; CYTOPLASM; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM;

BREAST NEOPLASMS; CELL MEMBRANE; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 84949547545     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.04.017     Document Type: Review

References (197)

1. Acconcial F., Marino M. The effects of 17β-estradiol in cancer are mediated by estrogen receptor signaling at the plasma membrane. Front Physiol 2011, 2:1-8.
2. Ahmad S., Singh N., Glazer R.I. Role of AKT1 in 17beta-estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem. Pharmacol 1999, 58:425-430.
3. Ahola T.M., Alkio N., Manninen T., Ylikomi T. Progestin and G protein-coupled receptor 30 inhibit mitogen-activated protein kinase activity in MCF-7 breast cancer cells. Endocrinology 2002, 143:4620-4626.
4. Al-Hajj M., Wicha M.S., Ito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:3983-3988.
5. Albanito L., Madeo A., Lappano R., Vivacqua A., Rago V., Carpino A., et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007, 67:1859-1866.
6. Altucci L., Addeo R., Cicatiello L., Dauvois S., Parker M.G., Truss M., et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G1-arrested human breast cancer cells. Oncogene 1996, 12:2315-2324.
7. Altucci L., Addeo R., Cicatiello L., Germano D., Pacilio C., Battista T., et al. Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus. Endocrinology 1997, 138:978-984.
8. Aronica S.M., Kraus W.L., Katzenellenbogen B.S. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc. Natl. Acad. Sci. U.S.A. 1994, 91:8517-8521.
9. Asselin-Labat M.-L., Vaillant F., Sheridan J.M., Pal B., Wu D., Simpson E.R., et al. Control of mammary stem cell function by steroid hormone signaling. Nature 2010, 465:798-802.
10. Barrón-González A., Castro Romero I. Re-expression of estrogen receptor alpha using a tetracycline-regulated gene expression system induced estrogen-mediated growth inhibition of the MDA-MB-231 breast cancer cell line. Biochem. Cell Biol 2004, 82(2):335-342.
11. Barton M. The membrane estrogen receptor GPER-Clues and questions. Steroids 2012, 77:935-942.
12. Berry M., Metzger D., Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 1990, 9:2811-2818.
13. Björnström L., Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol 2005, 19:833-842.
14. Bunone G., Briand P.A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15:2174-2183.
15. Castoria G., Barone M.V., Di Domenico M., Bilancio A., Ametrano D., Migliaccio A., et al. Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J. 1999, 18:2500-2510.
16. Castoria G., Migliaccio A., Bilancio A., Di Domenico M., de Falco A., Lombardi M., et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 2001, 20:6050-6059.
17. Cerillo G., Rees A., Manchanda N., Reilly C., Brogan I., White A., et al. The oestrogen receptor regulates NFkappaB and AP-1 activity in a cell-specific manner. J. Steroid Biochem. Mol. Biol 1998, 67:79-88.
18. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:302-313.
19. Chaudhri R.A., Olivares-Navarrete R., Cuenca N., Hadadi A., Boyan B.D., Schwartz Z. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-alpha36 (ERalpha36). J. Biol. Chem 2012, 287:7169-7181.
20. Chaudhri R.A., Schwartz N., Elbradie K., Schwartz Z., Boyan B.D. Role of ERalpha36 in membrane associated signaling by estrogens. Steroids 2012, 2012(81):74-80.
21. Chen Z., Yuhanna I.S., Galcheva-Gargova Z., Karas R.H., Mendelsohn M.E., Shaul P.W. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Invest 1999, 103:401-406.
22. Clark G.M. Prognostic and Predictive Factors. Diseases of the Breast 2000, vol. 2:489-514. Lippincott Williams & Wilkins.
23. Clark G.M., Osborne C.K., McGuire W.L. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J. Clin. Oncol 1984, 2:1102-1109.
24. Clarke R.B., Howell A., Potten C.S., Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997, 57:4987-4991.
25. Clarke R.B., Leonessa F., Welch J.N., Skaar T.C. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev 2001, 53:25-71.
26. Clarke R.B., Liu M.C., Bouker K.B., Gu Z., Lee R.Y., Zhu Y., et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003, 22:7316-7339.
27. Clarke R.B., Spence K., Anderson E., Howell A., Okano H., Potten C.S. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev. Biol 2005, 277:443-456.
28. Dauvois S., Danielian P.S., White R., Parker M.G. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:4037-4041.
29. Dean M., Fojo T., Bates S. Tumor stem cells and drug resistance. Nat. Rev. Cancer 2005, 5(4):275-284.
30. Deng H., Huang X., Fan J., Wang L.B., XIia Q., Yang X.P., et al. A variant of estrogen receptor-α, ER-α36 is expressed in human gastric cancer and is highly correlated with lymph node metastasis. Oncol. Rep 2010, 24:171-176. 1.
31. Deng H., Zhang X.T., Wang M.L., Zheng H.Y., Liu L.J., Wang Z.Y. ER-alpha36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor Cells. PLoS ONE 2014, e88034.
32. Deng H., Yin L., Zhang X.T., Liu L.J., Wang M.L., Wang Z.Y. ER-alpha variant ER-alpha 36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells. J. Steroid Biochem. Mol. Biol 2014, 144:417-426.
33. Deroo B.J., Buensuceso A.V. Minireview: estrogen receptor-beta: mechanistic insights from recent studies. Mol. Endocrinol 2010, 24:1703-1714.
34. Diaz-Chico B.N., Ogasawara Y., Chamness G.C., Salman M., McGuire W.L. A 46-kDa antigen associated with estrogen receptor in human breast cancer. J. Steroid Biochem 1988, 30:315-320.
35. Diehn M., Clarke M.F. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J. Natl. Cancer Inst 2006, 98(24):1755-1757.
36. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003, 17:1253-1270.
37. Dontu G., El-Ashry D., Wicha M.S. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol. Metab 2004, 15:193-197.
38. Driggers P.H., Segars J.H. Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol. Metab 2002, 13:422-427.
39. Dufy B., Vincent J.D., Fleury H., Du Pasquier P., Gourdji D., Tixier-Vidal A. Membrane effects of thyrotropin-releasing hormone and estrogen shown by intracellular recording from pituitary cells. Science 1979, 204:509-511.
40. Endoh H., Sasaki H., Maruyama K., Takeyama K., Waga I., Shimizu T., et al. Rapid activation of MAP kinase by estrogen in the bone cell line. Biochem. Biophys. Res. Commun 1997, 235:99-102.
41. Evans M.J., Eckert A., Lai K., Adelman S.J., Harnish D.C. Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo. Circ. Res 2001, 89:823-830.
42. Fawell S.E., White R., Hoare S., Sydenham M., Page M., Parker M.G. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:6883-6887.
43. Feigelson H.S., Henderson B.E. Estrogens and breast cancer. Carcinogenesis 1996, 17:2279-2284.
44. Filardo E., Quinn J., Pang Y., Graeber C., Shaw S., Dong J., et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007, 148:3236-3245.
45. Filardo E.J., Quinn J.A., Bland K.I., Frackelton A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol 2000, 14:1649-1660.
46. Fillmore C.M., Gupta P.B., Rudnick J.A., Caballero S., Keller P.J., Lander E.S., et al. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:21737-21742.
47. Flouriot G., Brand H., Denger S., Metivier R., Kos M., Reid G., et al. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO J. 2000, 19:4688-4700.
48. Fox E.M., Bernaciak T.M., Wen J., Weaver A.M., Shupnik M.A., Silva C.M. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol. Endocrinol 2008, 22:1781-1796.
49. Galluzzo P., Caiazza F., Moreno S., Marino M. Role of ER-beta palmitoylation in the inhibition of human colon cancer cell proliferation. Endocr. Relat. Cancer 2007, 14:153-167.
50. Gao F., Ma X., Ostmann A.B., Das S.K. GPR30 activation opposes estrogen estrogen dependent uterine growth via inhibition of stromal ERK1/2 and estrogen receptor alpha (ERalpha) phosphorylation signals. Endocrinology 2011, 152:1434-1447.
51. Garcia M., Derocq D., Freiss G., Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc. Natl. Acad. Sci. U.S.A. 1992, 89(23):11538-11542.
52. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 5:555-567.
53. Green S., Walter P., Kumar V., Krust A., Bornert J.M., Argos P., et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986, 320:134-139.
54. Greene G.L., Gilna P., Waterfield M., Baker A., Hort Y., Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986, 231:1150-1154.
55. Gu Q., Korach K.S., Moss R.L. Rapid action of 17beta-estradiol on kainate-induced currents in hippocampal neurons lacking intracellular estrogen receptors. Endocrinology 1999, 140:660-666.
56. Gupta P.B., Proia D., Cingoz O., Weremowicz J., Naber S.P., Weinberg R.A., et al. Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 2007, 67:2062-2071.
57. Hammes S.R., Levin E.R. Extranuclear steroid receptors: nature and actions. Endocr. Rev 2007, 28:726-741.
58. Han J.S., Crowe D.L. Tumor initiating cancer stem cells from human breast cancer cell lines. Int. J. Oncol 2009, 34:1449-1453.
59. Harnish D.C., Scicchitano M.S., Adelman S.J., Lyttle C.R., Karathanasis S.K. The role of CBP in estrogen receptor cross-talk with nuclear factor-kappaB in HepG2 cells. Endocrinology 2000, 141:3403-3411.
60. Harris H.A. Estrogen receptor-beta: recent lessons from in vivo studies. Mol. Endocrinol 2007, 21:1-13.
61. Hartman J., Lindberg K., Morani A., Inzunza J., Strom A., Gustafsson J.A. Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 2006, 66:11207-11213.
62. Howell A., Osborne C.K., Morris C., Wakeling A.E. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 2000, 89:817-825.
63. Jensen E.V., Cheng G., Palmieri C., Saji S., Makela S., Van Noorden S., et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:15197-15202.
64. Jiang H., Teng R., Wang Q., Zhang X.T., Wang H., Wang Z.Y., et al. Transcriptional analysis of estrogen receptor alpha variant mRNAs in colorectal cancers and their matched normal colorectal tissues. J. Steroid Biochem. Mol. Biol 2008, 112:20-24.
65. Jiang S.Y., Jordan V.C. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J. Natl. Cancer Inst 1992, 84:580-591.
66. Jordan N.J., Gee J.M., Barrow D., Wakeling A.E., Nicholson R.I. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res. Treat 2004, 87:167-180.
67. Jozan S., Julia A.M., Carretie A., Eche N., Maisongrosse V., Fouet B., et al. 65 and 47 kDa forms of estrogen receptor in human breast cancer: relation with estrogen responsiveness. Breast Cancer Res. Treat 1991, 19:103-109.
68. Kang L., Guo Y.M., Zhang X.T., Wang Z.Y. A positive cross-regulation of HER2 and ER-alpha36 controls ALDH1 positive breast cancer cells. J. Steroid Biochem. Mol. Biol 2011, 127:262-268.
69. Kang L.G., Wang Z.Y. Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-alpha36. J. Cell. Mol. Med 2010, 14:1485-1493.
70. Kang L.G., Zhang X.T., Xie Y., Tu Y.P., Wang D., Liu Z.M., et al. Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol. Endocrinol 2010, 24:709-721.
71. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchiyama S., Sasaki H., et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270:1491-1494.
72. Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2000, 2:335-344.
73. Katzenellenbogen B.S., Katzenellenbogen J.A. Biomedicine. Defining the "S" inSERMs. Science 2002, 295:2380-2381.
74. Kelly M.J., Levin E.R. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol. Metab 2001, 12:152-156.
75. Kelly M.J., Moss R.L., Dudley C.A. Differential sensitivity of preoptic-septal neurons to microelectrophoresed estrogen during the estrous cycle. Brain Res 1976, 114:152-157.
76. Kelly M.J., Moss R.L., Dudley C.A., Fawcett C.P. The specificity of the response of preoptic-septal area neurons to estrogen: 17alpha-estradiol versus 17beta-estradiol and the response of extrahypothalamic neurons. Exp. Brain Res 1977, 30:43-52.
77. Khan S.A., Rogers M.A., Obando J.A., Tamsen A. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 1994, 54:993-997.
78. Kim K.H., Bender J.R. Rapid, estrogen receptor-mediated signaling: why is the endothelium so special?. Sci. STKE 2005, 2005:pe28.
79. Kim R., Kaneko M., Arihiro K., Emi M., Tanabe K., Murakami S., et al. Extranuclear expression of hormone receptors in primary breast cancer. Ann. Oncol 2006, 17:1213-1220.
80. Klinge C.M. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001, 29:2905-2919.
81. Klinge C.M., Riggs K.A., Wickramasinghe N.S., Emberts C.G., McConda D.B., Barry P.N., et al. Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription. Mol. Cell. Endocrinol 2010, 323:268-276.
82. Kong E.H., Pike A.C., Hubbard R.E. Structure and mechanism of the oestrogen receptor. Biochem. Soc. Trans 2003, 31:56-59.
83. Korkaya H., Paulson A., Iovino F., Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130.
84. Korkaya H., Paulson A., Charfe-Jauffret E., Ginestier C., Brown M., Dutcher J., et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/β-catenin signaling. PLoS Biol 2009, 7:e1000121.
85. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novelreceptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:5925-5930.
86. Kushner P.J., Hort E., Shine J., Baxter J.D., Greene G.L. Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens. Mol. Endocrinol 1990, 4:1465-1473.
87. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., et al. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol 2000, 74:311-317.
88. Lazennec G., Bresson D., Lucas A., Chauveau C., Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001, 142:4120-4130.
89. Lee L.M., Cao J., Deng H., Chen P., Gatalica Z., Wang Z.Y. ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res 2008, 28:479-483.
90. Levin E.R. Cellular function of plasma membrane estrogen receptors. Steroids 2002, 67:471-475.
91. Levin E.R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol. Endocrinol 2003, 17:309-317.
92. Levin E.R. Plasma membrane estrogen receptors. Trends Endocrinol. Metab 2009, 20:477-482.
93. Li L., Haynes M.P., Bender J.R. Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4807-4812.
94. Lin S.L., Yan L.Y., Liang X.W., Wang Z.B., Wang Z.Y., Qiao J., et al. A novel variant of ER-alpha, ER-alpha 36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Reprod. Biol. Endocrinol 2009, 7:102-106.
95. Lin S.L., Yan L.Y., Zhang X.T., Yuan J., Li M., Qiao J., et al. ER alpha 36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS ONE 2010, 5:e9013.
96. Lindsey S.H., Yamaleyva L.M., Brosnihan K.B., Gallapher P.E., Chappell M.C. Estrogen receptor GPR30 reduces oxidative stress and proteinuria in the salt-sensitive female mRen2Lewis rat. Hypertension 2011, 58:665-671.
97. Lobenhofer E.K., Huper G., Iglehart J.D., Marks J.R. Inhibition of mitogen activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis. Cell Growth Differ 2000, 11:99-110.
98. Longo M., Brama M., Marino M., Bernardini S., Korach K.S., Wetsel W.C., et al. Interaction of estrogen receptor alpha with protein kinase C alpha and c-Src in osteoblasts during differentiation. Bone 2004, 34:100-111.
99. Lu Q., Pallas D.C., Surks H.K., Baur W.E., Mendelsohn M.E., Karas R.H. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:17126-17131.
100. Mahfoudi A., Roulet E., Dauvois S., Parker M.G., Wahli W. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:4206-4210.
101. Mallepell S., Krust A., Chambon P., Brisken C. Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:2196-2201.
102. Maret A., Clamens S., Delrieu I., Elhage R., Arnal J.F., Bayard F. Expression of the interleukin-6 gene is constitutive and not regulated by estrogen in rat vascular smooth muscle cells in culture. Endocrinology 1999, 140:2876-2882.
103. Margeat E., Bourdoncle A., Margueron R., Poujol N., Cavailles V., Royer C. Ligands differentially modulate the protein interactions of the human estrogen receptors alpha and beta. J. Mol. Biol 2003, 326:77-92.
104. Marino M., Galluzzo P., Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr. Genomics 2006, 7:497-508.
105. Marino M., Ascenzi P. Membrane association of estrogen receptor alpha and beta influences 17beta-estradiol-mediated cancer cell proliferation. Steroids 2008, 73:853-858.
106. Marquez D.C., Pietras R.J. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 2001, 20:5420-5430.
107. McDonnell D.P., Norris J.D. Connections and regulation of the human estrogen receptor. Science 2002, 296:1642-1644.
108. McKay L.I., Cidlowski J.A. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr. Rev 1999, 20:435-459.
109. McMillan J., Fatehi-Sedeh S., Sylvia V.L., Bingham V., Zhong M., Boyan B.D., et al. Sex-specific regulation of growth plate chondrocytes by estrogen is via multiple MAP kinase signaling pathways. Biochim. Biophys. Acta 2006, 1763:381-392.
110. Mermelstein P.G., Becker J.B., Surmeier D.J. Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J. Neurosci 1996, 16:595-604.
111. Metivier R., Penot G., Carmouche R.P., Hubner M.R., Reid G., Denger S., et al. Transcriptional complexes engaged by apo-estrogen receptor-alpha isoforms have divergent outcomes. EMBO J. 2004, 23:3653-3666.
112. Miceli V., Cocciadiferro L., Fregapane M., Zarcone M., Montalto G., Polito L.M., et al. Expression of wild-type and variant estrogen receptor alpha in liver carcinogenesis and tumor progression. OMICS 2011, 15:313-317.
113. Migliaccio A., Di Domenico M., Castoria G., de Falco A., Bontempo P., Nola E., et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation byestradiol-receptor complex in MCF-7 cells. EMBO J. 1996, 15:1292-1300.
114. Migliaccio A., Castoria G., Di Domenico M., de Falco A., Bilancio A., Lombardi M., et al. Sex steroid hormones act as growth factors. J. Steroid Biochem. Mol. Biol 2002, 83:31-35.
115. Migliaccio A., Castoria G., Di Domenico M., Ciociola A., Lombardi M., De Falco A., et al. Crosstalk between EGFR and extranuclear steroid receptors. Ann. N. Y. Acad. Sci 2006, 1089:194-200.
116. Moriarty K., Kim K.H., Bender J.R. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 2006, 147:5557-5563.
117. Morimoto K., Kim S.J., Tanei T., Shimazu K., Tanji Y., Taguchi T., et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 2009, 100:1062-1068.
118. Morley P., Whitfield J.F., Vanderhyden B.C., Tsang B.K., Schwartz J.L. A new, nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology 1992, 131:1305-1312.
119. Nethrapalli I.S., Tinnikov A.A., Krishnan V., Lei C.D., Toran-Allerand C.D. Estrogen activates mitogen-activated protein kinase in native, nontransfected CHO-K1, COS-7, and RAT2 fibroblast cell lines. Endocrinology 2005, 146:56-63.
120. Nicholson R.I., Gee J.M., Manning D.L., Wakeling A.E., Montano M.M., Katzenellenbogen B.S. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen sensitive and resistant experimental and clinical breast cancer. Ann. N. Y. Acad. Sci 1995, 761:148-163.
121. Nilsson S., Makela S., Treuter E., Tujague M., Thomsen J., Andersson G., et al. Mechanisms of estrogen action. Physiol. Rev 2001, 81:1535-1565.
122. Nissen-Meyer R. "Prophylactic" ovariectomy and ovarian irradiation in breast cancer. Acta Unio Int. Contra Cancrum 1964, 20:527-530.
123. Normanno N., Di Maio M., De Maio E., De Luca A., Matteis A.D., Giordano A., et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 2005, 12:721-747.
124. O'Brien C.S., Howell S.J., Farnie G., Clarke R.B. Resistance to endocrine therapy: are breast cancer stem cells culprits. J. Mammary Gland Biol. Neoplasia 2009, 14(1):45-54.
125. Ogawa S., Inoue S., Watanabe T., Orimo A., Hosoi T., Ouchi Y., et al. Molecular cloning and characterization of human estrogen receptor-βcx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 1998, 26(15):3505-3512.
126. Ohshiro K., Schwartz A.M., Levine P.H., Kumar R. Alternate estrogen receptors promote invasion of inflammatory breast cancer cells via non-genomic signaling. PLoS ONE 2012, 7:e30725.
127. Oliveira L.R., Jeffrey S.S., Ribeiro-Silva A. Stem cells in human breast cancer. Histol. Histopathol 2010, 25:371-385.
128. Osborne C.K., Yochmowitz M.G., Knight W.A., McGuire W.L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980, 46:2884-2888.
129. Otto C., Rohde-Schulz B., Schwarz G., Fuchs I., Klewer M., Brittain D., et al. G protein-coupled receptor 30 localizes to the endoplasmic reticulum and is not activated by estradiol. Endocrinology 2008, 149:4846-4856.
130. Otto C., Fuchs I., Kauselmann G., Kern H., Zevnik B., Andreasen P., et al. GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol. Reprod 2009, 80:34-41.
131. Paruthiyil S., Parmar H., Kerekatte V., Cunha G.R., Firestone G.L., Leitman D.C. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004, 64:423-428.
132. Pearce S.T., Liu H., Jordan V.C. Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J. Biol. Chem 2003, 278:7630-7638.
133. Pedram A., Razandi M., Levin E.R. Nature of functional estrogen receptors at the plasma membrane. Mol. Endocrinol 2006, 20:1996-2009.
134. Pelekanou V., Notas G., Kampa M., Tsentelierou E., Radojicic J., Leclercq G., et al. ERalpha36, a new variant of the ERalpha is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines. Steroids 2012, 77(10):928-934.
135. Penot G., Le Peron C., Merot Y., Grimaud-Fanouillere E., Ferriere F., Boujrad N., et al. The human estrogen receptor-alpha isoform hERalpha46 antagonizes the proliferative influence of hERalpha66 in MCF7 breast cancer cells. Endocrinology 2005, 146:5474-5484.
136. Pietras R.J., Szego C.M. Endometrial cell calcium and oestrogen action. Nature 1975, 253:357-359.
137. Pietras R.J., Szego C.M. Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 1977, 265:69-72.
138. Pietras R.J., Marquez D.C., Chen H.W., Tsai E., Weinberg O., Fishbein M. Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 2005, 70:372-381.
139. Pilat M.J., Christman J.K., Brooks S.C. Characterization of the estrogen receptor transfected MCF10A breast cell line 139B6. Breast Cancer Res. Treat 1996, 37:253-266.
140. Piva M., Domenici G., Iriondo O., Rábano M., Simões B.M., Comaills V., et al. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO Mol Med 2013, 5:1-14.
141. Prall O.W., Rogan E.M., Sutherland R.L. Estrogen regulation of cell cycle progression in breast cancer cells. J. Steroid Biochem. Mol. Biol 1998, 65:169-174.
142. Prossnitz E.R., Barton M. The G protein-coupled estrogen receptor GPER in health and disease. Nat. Rev. Endocrinol 2011, 7:715-726.
143. Rao B.R. Isolation and characterization of an estrogen binding protein which may integrate the plethora of estrogenic actions in non-reproductive organs. J. Steroid Biochem. Mol. Biol 1998, 65:3-41.
144. Razandi M., Pedram A., Greene G.L., Levin E.R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ER-alpha and ER-beta expressed in Chinese hamster ovary cells. Mol. Endocrinol 1999, 13:307-319.
145. Razandi M., Pedram A., Park S.T., Levin E.R. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem 2003, 278(4):2701-2712.
146. Rebbeck T.R., Levin A.M., Eisen A., Snyder C., Watson P., Cannon-Albright L., et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl. Cancer Inst 1999, 91:1475-1479.
147. Revankar C.M., Cimino D.F., Sklar L.A., Arterburn J.B., Prossnitz E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005, 307:1625-1630.
148. Ring A., Dowsett M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 2004, 11:643-658.
149. Robertson J.F. Oestrogen receptor: a stable phenotype in breast cancer. Br. J. Cancer 1996, 73:5-12.
150. Rochefort H. Oestrogen- and anti-oestrogen-regulated genes in human breast cancer. Ciba Found. Symp 1995, 191:254-265.
151. Roger P., Daures J.P., Maudelonde T., Pignodel C., Gleizes M., Chapelle J., et al. Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors. Hum. Pathol 2000, 31:593-600.
152. Roger P., Sahla M.E., Makela S., Gustafsson J.A., Baldet P., Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 2001, 61:2537-2541.
153. Russell K.S., Haynes M.P., Sinha D., Clerisme E., Bender J.R. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:5930-5935.
154. Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam. Horm 2001, 62:231-252.
155. Segars J.H., Driggers P.H. Estrogen action and cytoplasmic signaling cascades. Part I: membrane-associated signaling complexes. Trends Endocrinol. Metab 2002, 13:349-354.
156. Shang Y.F., Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002, 295:2465-2468.
157. Shi L., Dong B., Li Z., Lu Y., Ouyang T., Li J., et al. Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. J. Clin. Oncol 2009, 27:3423-3429.
158. Shoker B.S., Jarvis C., Clarke R.B., Anderson E., Hewlett J., Davies M.P., et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am. J. Pathol 1999, 155:1811-1815.
159. Shoker B.S., Jarvis C., Sibson D.R., Walker C., Sloane J.P. Oestrogen receptor expression in the normal and pre-cancerous breast. J. Pathol 1999, 188:237-244.
160. Shupnik M.A. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 2004, 23:7979-7989.
161. Sleeman K.E., Kendrick H., Robertson D., Isacke C.M., Ashworth A., Smalley M.J. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J. Cell Biol 2007, 176:19-26.
162. Song R.X., McPherson R.A., Adam L., Bao Y., Shupnik M.A., Kumar R., et al. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol. Endocrinol 2002, 16:116-127.
163. Song R.X., Zhang Z., Chen Y., Bao Y., Santen R.J. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 2007, 148(8):4091-4101.
164. Speir E., Yu Z.X., Takeda K., Ferrans V.J., Cannon R.O. Competition for p300 regulates transcription by estrogen receptors and nuclear factor-kappaB in human coronary smooth muscle cells. Circ. Res 2000, 87:1006-1011.
165. Sun L., Wang J., Zhang L., Li X., Shen D. Expression of ER-α36, a novel variant of estrogen receptor in endometrial carcinoma and its clinical significance. Gynecol. Obstet. Invest 2013, 75(1):68-72.
166. Sylvia V.L., Walton J., Lopez D., Dean D.D., Boyan B.D., Schwartz Z. 17 beta Estradiol-BSA conjugates and 17 beta-estradiol regulate growth plate chondrocytes by common membrane associated mechanisms involving PKC dependent and independent signal transduction. J. Cell. Biochem 2001, 81:413-429.
167. Tesarik J., Mendoza C. Direct non-genomic effects of follicular steroids on maturing human oocytes: oestrogen versus androgen antagonism. Hum. Reprod. Update 1997, 3:95-100.
168. Tong J.S., Zhang Q.H., Wang Z.B., Li S., Yang C.R., Fu X.Q., et al. ER-alpha36, a novel variant of ER-alpha, mediates estrogen stimulated proliferation of endometrial carcinoma cells via the PKCdelta/ERK pathway. PLoS ONE 2010, 5:e15408.
169. Toran-Allerand C.D. Estrogen and the brain beyond ER-α, ER-β, and 17β-Estradiol. Ann. N. Y. Acad. Sci 2005, 1052:136-144.
170. Toran-Allerand C.D., Guan X., MacLusky N.J., Horvath T.L., Diano S., Singh M., et al. ER-X: a novel, plasma membrane associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J. Neurosci 2002, 22:8391-8401.
171. Touitou I., Mathieu M., Rochefort H. Stable transfection of the estrogen receptor cDNA into Hela cells induces estrogen responsiveness of endogenous cathepsin D gene but not of cell growth. Biochem. Biophys. Res. Commun 1990, 169:109-115.
172. Tsai E.M., Wang S.C., Lee J.N., Hung M.C. Akt activation by estrogen in estrogen receptor-negative breast cancer cells. Cancer Res 2001, 61:8390-8392.
173. Tu B.B., Lin S.L., Yan L.Y., Wang Z.-Y., Sun Q.Y., Qiao J. ER- alpha 36, a novel variant of estrogen receptor alpha, is involved in EGFR-related carcinogenesis in endometrial cancer. Am. J. Obstet. Gynecol 2011, 205(227):e1-e6.
174. Tzukerman M.T., Esty A., Santiso-Mere D., Danielian P., Parker M.G., Stein R.B., et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol 1994, 8:21-30.
175. Vranic S., Gatalica Z., Deng H., Frkovic-Grazio S., Lee M.J., Olga Gurjeva O., et al. ER-alpha36, a novel isoform of ER- alpha 66, is commonly over-expressed in apocrine and adenoid cystic carcinomas of the breast. J. Clin. Pathol 2011, 64:54-57.
176. Wade C.B., Robinson S., Shapiro R.A., Dorsa D.M. Estrogen receptor (ER) alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway. Endocrinology 2001, 142(6):2336-2342.
177. Wagner E.F., Nebreda A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat. Rev. Cancer 2009, 9:537-549.
178. Wallacides A., Chesnel A., Ajj H., Chillet M., Flament S., Dumond H. Estrogens promote proliferation of the seminoma-like TCam-2 cell line through a GPER-dependent ERalpha36 induction. Mol. Cell. Endocrinol 2012, 350:61-71.
179. Wang J., Li J., Fang R., Xie S., Wang L., Xu C. Expression of ERalpha36 in gastric cancer samples and their matched normal tissues. Oncol Lett 2012, 3:172-175.
180. Wang Z.Y., Zhang X.T., Shen P., Loggie B.W., Chang Y., Deuel T.F. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem. Biophys. Res. Commun 2005, 336:1023-1027.
181. Wang Z.Y., Zhang X.T., Shen P., Loggie B.W., Chang Y., Deuel T.F. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:9063-9068.
182. Warner M., Saji S., Gustafsson J.A. The normal and malignant mammary gland: a fresh look with ER-beta onboard. J. Mammary Gland Biol. Neoplasia 2000, 5:289-294.
183. Watson C., Norfleet A., Pappas T., Gametchu B. Rapid actions of estrogens in GH3/B6 pituitary tumor cells via a plasma membrane version of estrogen receptor- alpha. Steroids 1999, 64:5-13.
184. Watters J.J., Campbell J.S., Cunningham M.J., Krebs E.G., Dorsa D.M. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signaling cascade and c-fos immediate early gene transcription. Endocrinology 1997, 138:4030-4033.
185. Woodward W.A., Chen M.S., Behbod F., Alfaro M.P., Buchholz T.A., Rosen J.M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:618-623.
186. Yamashita H., Iwase H., Toyama T., Fujii Y. Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene 2003, 22:1638-1652.
187. Yin L., Zhang X.T., Bian X.W., Guo Y.M., Wang Z.Y. Disruption of the ER-alpha36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells. PLoS ONE 2014, 9(9):e107369.
188. Yu L.F., Ke W., Wang Y.L., Ding W., Wang B., Sui Huang S., et al. Predictive and prognostic value of ER- alpha 36 expression in breast cancer patients treated with chemotherapy. Steroids 2014, 84:11-16.
189. Zeps N., Bentel J.M., Papadimitriou J.M., Dawkins H.J. Murine progesterone receptor expression in proliferating mammary epithelial cells during normal pubertal development and adult estrous cycle; association with ER-alpha and ER-beta status. J. Histochem. Cytochem 1999, 47:1323-1330.
190. Zhang J., Li G., Li Z., Yu X., Zheng Y., Jin K., et al. Estrogen-independent effects of ER-alpha36 in ER-negative breast cancer. Steroids 2012, 77:666-673.
191. Zhang X.T., Wang Z.-Y. Estrogen receptor- alpha variant, ER- alpha 36, is involved in tamoxifen resistance and estrogen hypersensitivity. Endocrinology 2013, 154:1990-1998.
192. Zhang X.T., Kang L.G., Ding L., Vranic S., Gatalica Z., Wang Z.Y. A positive feedback loop of ER-alpha36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 2011, 30:770-780.
193. Zhang X.T., Ding L., Kang L.G., Wang Z.-Y. Estrogen receptor alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells. PLoS ONE 2012, 7(1):e30174.
194. Zhang X.T., Deng H., Wang Z.Y. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-alpha36 in ER-positive breast cancer cells. J. Steroid Biochem. Mol. Biol 2014, 143:434-443.
195. Zhao L., O'Neill K., Brinton R.D. Estrogenic agonist activity of ICI 182,780 (Faslodex) in hippocampal neurons: implications for basic science understanding of estrogen signaling and development of estrogen modulators with a dual therapeutic profile. J. Pharmacol. Exp. Ther 2006, 319:1124-1132.
196. Zheng W.H., Andersson S., Cheng G., Simpson E.R., Warner M., Gustafsson J.A. Update on estrogen signaling. FEBS Lett 2003, 546:17-24.
197. Zou Y., Ding L., Coleman M., Wang Z.Y. Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha 36. FEBS Lett 2009, 583:1368-1374.